Author: Kazi Hasan Kazi is a seasoned pharmaceutical industry professional with over 20 years of experience specializing in production operations, quality management, and process validation
SCS for DPN: Medical benefit (Part B/commercial) with center criteria, documented refractory pain, and failed med trials
That number is not just large in absolute terms, it is the largest weight-loss signal ever reported in a randomized Phase 3 trial of a GLP-1-class compound, and it arrived with additional secondary findings that reframe what "GLP-1 therapy" could eventually mean: a 75.8% reduction in osteoarthritis pain, a roughly 20% drop in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia in the affected subpopulation
See Figure 2
Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and dose logging, side-effect monitoring, and more
2019pii: S1751-9918(19)30004-X
